Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Sells $127,500.00 in Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Michael Joseph Driscoll sold 25,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares of the company’s stock, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Organogenesis Stock Down 8.5 %

Shares of NASDAQ ORGO opened at $5.16 on Friday. The stock has a market cap of $654.43 million, a PE ratio of -86.00 and a beta of 1.66. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 52-week low of $2.17 and a 52-week high of $6.71. The business has a 50-day moving average price of $3.65 and a 200 day moving average price of $3.35.

Institutional Trading of Organogenesis

A number of hedge funds have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. lifted its position in Organogenesis by 5.4% during the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock worth $39,952,000 after acquiring an additional 645,000 shares during the period. Assenagon Asset Management S.A. lifted its position in Organogenesis by 54.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock worth $9,443,000 after acquiring an additional 1,035,120 shares during the period. Dimensional Fund Advisors LP lifted its position in Organogenesis by 18.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock worth $8,925,000 after acquiring an additional 442,772 shares during the period. State Street Corp lifted its position in Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after acquiring an additional 9,090 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Organogenesis by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company’s stock worth $3,435,000 after acquiring an additional 255,600 shares during the period. 49.57% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upped their target price on Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.